Find recruiting clinical trials for kidney cancer (renal cell carcinoma) in the UK — including immunotherapy combinations, HIF-2α inhibitors, antibody-drug conjugates, and the UK-wide RAMPART adjuvant platform trial. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Cancer confined to the kidney or local lymph nodes
Standard: Partial or radical nephrectomy, active surveillance for small renal masses, thermal ablation
After nephrectomy — reducing recurrence risk
Standard: Pembrolizumab for high-risk RCC, sunitinib (less common now), or surveillance
Metastatic disease at diagnosis or progression after nephrectomy
Standard: Ipilimumab + nivolumab, pembrolizumab + axitinib, or cabozantinib + nivolumab
Progression after first-line immunotherapy or targeted therapy
Standard: Cabozantinib, lenvatinib + everolimus, belzutifan for HIF-2α, further immunotherapy options
Bispecific antibodies targeting PD-1 and VEGF, next-generation CTLA-4 blockers, and combination checkpoint inhibition with HIF-2α inhibitors are among the most active research areas in advanced RCC.
The UK's multicentre, multi-arm, adaptive platform trial testing adjuvant therapies after nephrectomy. Multiple treatment arms allow patients to be randomised to the most promising new agents based on their risk profile and biomarkers.
Belzutifan is the first approved HIF-2α inhibitor, targeting the hypoxia pathway central to clear cell RCC. Trials are now testing next-generation agents in this class and combinations with immunotherapy.
Carbonic anhydrase IX (CAIX) is highly expressed on clear cell RCC cells but not normal kidney tissue. Antibody-drug conjugates and chimeric antigen receptor (CAR) T-cells targeting CAIX are in early-phase trials in the UK.
Loading trials from ClinicalTrials.gov...
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for about 90% of cases. Other types include transitional cell carcinoma of the renal pelvis and Wilms' tumour in children.
Yes. Ipilimumab + nivolumab is now standard for intermediate/poor-risk RCC, and trials are testing new combinations — including pembrolizumab with belzutifan (HIF-2α inhibitor) and novel bispecific antibodies.
Yes. Adjuvant trials specifically recruit patients after nephrectomy to test whether immunotherapy or targeted therapy can reduce the risk of recurrence. The RAMPART platform trial in the UK is a key example.
New HIF-2α inhibitors (belzutifan), next-generation tyrosine kinase inhibitors, and ADCs targeting CAIX — an antigen highly expressed on clear cell RCC — are all in active development.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.